Background
Phase 3 double-blind, double-dummy RCT. 21,105 patients with non-valvular AF and CHADS2 score ≥2 in 46 countries. Edoxaban (Savaysa/Lixiana) is a once-daily direct oral factor Xa inhibitor. ENGAGE-AF is the largest AF DOAC trial. Two edoxaban doses tested: 60 mg qd (high-dose) and 30 mg qd (low-dose), both with prespecified 50% dose reduction for specific factors (CrCl 30-50 mL/min, weight ≤60 kg, P-gp inhibitor use). Median follow-up 2.8 years.
Interventions and follow up
Arm A: Edoxaban 60 mg orally once daily (or 30 mg if dose-reduction criteria)
Arm B: Warfarin dose-adjusted to INR 2.0–3.0
Primary endpoint: Stroke (ischemic or hemorrhagic) or systemic embolism
mFollow up: 2.8 years (median)
Arm B: Warfarin dose-adjusted to INR 2.0–3.0
Primary endpoint: Stroke (ischemic or hemorrhagic) or systemic embolism
mFollow up: 2.8 years (median)
Results
Stroke/systemic embolism (60mg vs warfarin): 1.18%/yr vs 1.50%/yr, HR 0.79 (95% CI 0.63–0.99), P<.001 for non-inferiority; P=.08 for superiority
Major bleeding (60mg): 2.75%/yr vs 3.43%/yr, HR 0.80 (0.71–0.91), P<.001
ICH (60mg): 0.39%/yr vs 0.85%/yr, HR 0.47 (0.34–0.63), P<.001
GI bleeding (60mg): 1.51%/yr vs 1.23%/yr (edoxaban higher, P=.03)
Cardiovascular mortality (60mg): 2.74%/yr vs 3.17%/yr, P=.013
Major bleeding (60mg): 2.75%/yr vs 3.43%/yr, HR 0.80 (0.71–0.91), P<.001
ICH (60mg): 0.39%/yr vs 0.85%/yr, HR 0.47 (0.34–0.63), P<.001
GI bleeding (60mg): 1.51%/yr vs 1.23%/yr (edoxaban higher, P=.03)
Cardiovascular mortality (60mg): 2.74%/yr vs 3.17%/yr, P=.013
Adverse events
Main adverse events: GI bleeding higher with edoxaban 60mg vs warfarin. ICH substantially reduced. Overall major bleeding reduced. No hepatotoxicity. No dietary restrictions. Dyspepsia less frequent than dabigatran. Dose reduction in ~25% of patients based on criteria. Discontinuation rates ~30% each arm over 2.8 years.
Conclusions
Edoxaban 60 mg once daily was non-inferior to warfarin for stroke prevention in AF with significantly lower major bleeding and ICH, establishing it as an effective DOAC option, though superiority for stroke was not achieved.
Key Limitations
Key Limitations: Warfarin TTR was 68.4% (best among AF DOAC trials). Stroke non-inferiority but not superiority (P=.08) — less striking than apixaban/dabigatran superiority findings. GI bleeding is higher with edoxaban 60mg. Pre-specified dose reduction for multiple factors creates complexity. Ischemic stroke reduction less pronounced than with apixaban in ARISTOTLE. Once-daily is convenient but peak-to-trough PK variation may affect ischemic stroke protection throughout the day.
Clinical Context
FDA approved January 2015 (Savaysa) for non-valvular AF. Edoxaban requires transition from parenteral anticoagulation (not used in naïve AF patients without bridging). Less widely adopted than apixaban or rivaroxaban in the US. Once-daily dosing offers adherence advantage. Specific reversal: andexanet alfa. Used more commonly in Europe and Asia. Not preferred when transitioning from parenteral anticoagulation is not feasible.
References